Vericel Corp (VCEL): Total Assets
$487.97M
As of 2025-12-31
$502.87M
As of 2026-06-30
+21.4%
3-year compound annual growth
+18.9%
5-year compound annual growth
+30.4%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $487.97M | +12.8% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $432.72M | +22.4% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $353.66M | +29.5% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $273.00M | +12.0% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $243.71M | +18.5% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $205.61M | +34.2% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $153.24M | +29.1% | 2021-02-24, Balance as of period end |
| 2018-12-31 | $118.69M | +117.5% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $54.58M | +12.3% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $48.60M | +41.6% | 2018-03-05, Balance as of period end |
| 2015-12-31 | $34.31M | -27.9% | 2017-03-13, Balance as of period end |
| 2014-12-31 | $47.58M | +416.3% | 2016-03-14, Balance as of period end |
| 2013-12-31 | $9.21M | -39.3% | 2015-03-25, Balance as of period end |
| 2012-12-31 | $15.18M | +96.1% | 2014-03-13, Balance as of period end |
| 2011-12-31 | $7.74M | -76.4% | 2013-03-18, Balance as of period end |
| 2010-12-31 | $32.83M | n/a | 2012-03-15, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Vericel Corp (VCEL) | 2025-12-31 | $487.97M | +12.8% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $512.74M | -4.9% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $913.17M | +0.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $641.86M | +4.5% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $1.33B | +26.3% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $1.07B | +5.7% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $245.96M | -13.0% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $453.03M | -2.8% |
Compare VCEL, ADPT, IOVA, VXRT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗